Experimental and human data suggest that adverse cardiovascular (CV) and renal effects of aldosterone excess are dependent on concomitant dietary salt intake. Increased urinary protein (Uprot) is an early sign of nephropathy independently associated with CV risk. We have previously reported a positive association between Uprot and urinary sodium (UNa) in patients with hyperaldosteronism, but not in patients with normal aldosterone levels. We aimed to determine whether Uprot is related to UNa in patients with aldosterone-producing adenoma (APA) and whether the degree of Uprot and strength of this relationship is reduced following correction of hyperaldosteronism. Subjects with APA (n ¼ 24) underwent measurement of 24 h Uprot and UNa before and after unilateral adrenalectomy (follow-up 15.0 ± 11.9 months). Following surgery, mean clinic systolic blood pressure fell (150.4±18.2 vs 134.5±14.5 mm Hg, P ¼ 0.0008), despite a reduction in number of antihypertensive medications, and Uprot (211.2 ± 101.6 vs 106.0 ± 41.8 mg per day, Po0.0001) decreased. There was a positive correlation between Uprot and UNa both before (r ¼ 0.5477, P ¼ 0.0056) and after (r ¼ 0.5097, P ¼ 0.0109) adrenalectomy. Changes in UNa independently predicted Uprot reduction (P ¼ 0.0189). These findings suggest that both aldosterone levels and dietary salt contribute to renal damage, and that once glomerular damage occurs it is not completely resolved following correction of hyperaldosteronism. Our study suggests that treatment strategies based on reduction of aldosterone effects, by adrenalectomy or mineralocorticoid receptor blockade, in conjunction with low-salt diet would provide additional target-organ protection in patients with primary aldosteronism.
Introduction
Primary aldosteronism (PA) was first described by Conn in 1955 1 and is defined as a group of disorders in which aldosterone production is inappropriately high for prevailing sodium/volume status and autonomous of its usual chronic regulator, renin/angiotensin II. 2 PA is a common secondary cause of high blood pressure (BP) with a prevalence among hypertensive patients that may be as high as 5-15%. [2] [3] [4] [5] [6] [7] Unilateral forms of PA, including aldosterone-producing adenoma (APA), have comprised 30-50% of patients with PA in recent series [7] [8] [9] and laparoscopic unilateral adrenalectomy has resulted in cure of hypertension in 50-80% and improvement in 100% of patients. [10] [11] [12] Excessive aldosterone secretion leads to excessive sodium and fluid retention and consequentially hypertension. Furthermore, experimental studies have demonstrated that aldosterone promotes targetorgan (including heart, brain and kidney) deterioration, which is independent of BP and characterized by perivascular inflammation and necrosis progressing to fibrosis. [13] [14] [15] [16] In the kidneys, rats treated with aldosterone infusion and 1% salt diet developed severe vascular and glomerular sclerosis, fibrinoid necrosis and thrombosis, interstitial leukocyte infiltration, tubular damage, and increased expression of proinflammatory molecules and albuminuria compared with controls. 17 Treatment with eplerenone, a specific mineralocorticoid receptor blocker, reduced osteopontin, albuminuria and proinflammatory gene expression. These aldosterone-induced pathological changes appear to be dependent on concomitant intake of high-salt diet, suggesting that the deleterious effect of aldosterone may be minimized or even prevented under normal or low-salt diet. 18 Urinary protein (Uprot) excretion is a marker of generalized vascular dysfunction and an early sign of nephropathy associated with progressive glomerulosclerosis, tubulointerstitial inflammation and scarring, leading to progressive deterioration in renal function in both diabetic and nondiabetic individuals. 19 Proteinuria is also independently associated with increases in cardiovascular (CV) events and all-cause and CV mortalities. [20] [21] [22] [23] [24] Patients with PA, regardless of whether due to APA or bilateral adrenal hyperplasia, have higher Uprot excretion than patients with essential hypertension and similar BP. [25] [26] [27] Furthermore, urinary albumin excretion rate is higher in patients with APA than in those with bilateral adrenal hyperplasia. 25 We have previously described a positive correlation between Uprot and urinary sodium (UNa) in hypertensive patients with aldosterone excess but not in patients with normal aldosterone, despite similar BP. 28 As we have already demonstrated that there is no positive correlation between Uprot and UNa in patients with essential hypertension, we aimed to confirm that Uprot is related to UNa in patients with APA and to see whether the degree of Uprot and strength of this relationship is reduced following correction of hyperaldosteronism by unilateral adrenalectomy.
Subjects and methods

Subjects
Patients referred to the Endocrine Hypertension Research Centre at Greenslopes and Princess Alexandra Hospitals, University of Queensland School of Medicine, Australia, who were subsequently confirmed as having PA due to APA and underwent adrenalectomy were included. The study was approved by the Institutional Review Committee. The records of these patients were carefully reviewed and (1) age, sex and duration of hypertension, and (2) BP levels, antihypertensive medications and results of blood and urine tests before and after adrenalectomy were recorded. The follow-up after adrenalectomy ranged from 5 to 45 months. Seated-office BP was measured after having the subject sit for at least 5 min according to current guidelines. 29 Diabetic patients were excluded.
Diagnosis of primary aldosteronism
As per our usual clinical protocol, 30 the plasma aldosterone/renin ratio was measured in all-referred hypertensive patients, whether or not hypokalemic, in blood collected midmorning from upright subjects after correction of potassium levels using oral potassium supplements, and while taking a liberal sodium diet. Before collection, diuretics (including spironolactone and amiloride) were ceased for at least 6 weeks, and wherever possible, b-adrenoreceptor blockers, clonidine, a-methyldopa, dihydropyridine-type calcium channel antagonists, angiotensin-converting enzyme inhibitors or angiotensin II receptor antagonists for at least 2 weeks and replaced with noninterfering medications, such as slow-release verapamil (with or without hydralazine) and/or prazosin, to maintain control of hypertension.
Patients with aldosterone/renin ratio greater than 25 (plasma aldosterone concentration in ng per 100 ml, plasma renin activity (PRA) in ng ml À1 per h) on at least two occasions were encouraged to undergo a fludrocortisone suppression test (FST) to definitively confirm or exclude PA. 30 The diagnosis of PA was considered established when plasma aldosterone concentration, measured at 1000 h in seated patients after at least 2 h upright, failed to suppress to below 6 ng per 100 ml at the conclusion of 4 days administration of a high-sodium diet, slow-release sodium chloride (slow Na 30 mmol, three times daily with meals), and fludrocortisone acetate (0.1 mg every 6 h), provided that: (1) upright PRA was suppressed to less than 1.0 ng ml À1 per h; (2) plasma potassium was within the normal range; and (3) plasma cortisol was lower at 1000 h than at 0800 h, excluding an acute increase in adrenocorticotropic hormone that may have prevented suppression of aldosterone.
Hybrid gene or dexamethasone suppression testing for familial glucocorticoid-suppressible hyperaldosteronism 31 was negative in all patients included in this study. Adrenal computed tomography was performed with fine (2.5-3.0 mm) slices. Regardless of computed tomography findings, all patients underwent adrenal venous sampling to differentiate unilateral from bilateral autonomous aldosterone overproduction. Adrenal venous sampling was considered to show lateralization if: (1) adrenal venous cortisol levels were Xthree times higher than peripheral venous cortisol levels, confirming successful cannulation of adrenal veins; (2) adrenal venous aldosterone/cortisol ratios on one side were Xtwo times higher than peripheral and (3) adrenal venous aldosterone/cortisol ratios on the other side were not higher than peripheral (contralateral suppression). Histological analysis of the removed gland confirmed adenoma and negative FST after adrenalectomy confirmed biochemical cure of PA in all patients.
Laboratory assessment Levels of plasma potassium, plasma aldosterone concentration and PRA or plasma renin concentration (PRC) were measured in blood carefully collected (to avoid stasis) midmorning after at least 2 h of upright posture. 32 A single 24-h urine collection for urinary aldosterone (Ualdo), UNa, potassium (UK), Uprot and creatinine measurement was obtained during the subject's usual diet-reflecting salt appetite. The method for estimating renin was replaced in 2002 from PRA (expressed in ng ml À1 per h) 33 with PRC (expressed in mU l À1 ). 34 To permit group analyses of renin, PRC values were transformed to PRA by dividing PRC by 8.4. PRA was measured by radioimmunoassay of generated angiotensin I PRC was measured by chemiluminescent immunoassay technology. The methods for plasma aldosterone concentration and Ualdo changed, during 2003, from radioimmunoassay 35 to a radioimmunometric method. 36 UNa, UK and Uprot were measured by commercial laboratories using standard techniques. Creatinine clearance was calculated from the serum creatinine and the urinary creatitine. For the purpose of calculating aldosterone/renin ratio, PRA levels that were undetectable were taken to be 0.15 ng ml À1 per h and PRC were taken to be 2 mU l À1 , which was the lower limit of detection with these assay techniques.
Statistical methods
Values are expressed as mean ± s.d. unless stated otherwise. BP and laboratory tests were compared before and after adrenalectomy using paired t-tests for normally distributed and Wilcoxon-matched paired tests for non-normally distributed variables. Categorical variables were compared using Fisher's exact test. UNa and Uprot were evaluated by linear regression analysis. Multiple regression analysis was performed to explore the determinants of Uprot changes after adrenalectomy. A P-value of o0.05 was considered significant.
Results
A total of 24 patients were included. Demographic characteristics are listed in Table 1 . Number of antihypertensive medications decreased significantly (from 2.0 ± 1.1 to 0.7 ± 1.1; P ¼ 0.0002) after adrenalectomy (Table 2) (Figure 2 ). There was no significant correlation between Ualdo and Uprot either before or after adrenalectomy. Changes in plasma potassium, systolic BP, UNa and Ualdo after adrenalectomy were evaluated as independent predictors of Uprot reduction by multivariate analysis. Although Ualdo, systolic BP and potassium did not predict Uprot changes after adrenalectomy, UNa significantly predicted Uprot reduction (P ¼ 0.0189).
Discussion
The current results demonstrate that unilateral adrenalectomy in patients with APA markedly reduces Uprot excretion, and that there is a positive correlation between sodium excretion and proteinuria before adrenalectomy that is not reversed after APA removal in spite of BP reduction and biochemical correction of PA.
Previous studies demonstrated that patients with PA have increased Uprot excretion compared with patients with essential hypertension despite similar BP and that treatment of PA reduces proteinuria. [25] [26] [27] In one study, urinary albumin/creatinine ratio decreased by 36% after a mean of 9 years of treatment in patients with PA treated with either adrenalectomy or spironolactone compared with only 20% among patients with essential hypertension treated with nonspecific antihypertensives. 37 In another study, urinary albumin was reduced by 45% in 25 patients with APA treated with adrenalectomy. 27 In this study, BP-related factors may have contributed, because systolic BP decreased significantly after adrenalectomy. However, the multivariate analysis in this study and the findings of previous studies reporting greater degrees of proteinuria in patients with PA vs essential hypertensives matched for BP, and greater falls, following specific surgical or medical treatment (despite similar reductions in BP) compared with essential hypertensives treated with nonspecific antihypertensives, argue for the involvement of other BP-independent effects.
Hyperfiltration has been implicated as one of the main determinants of aldosterone-related proteinuria. 27 ,37,38 Sechi et al. 37 showed that patients with PA had significantly higher glomerular filtration rate Adrenalectomy and protein excretion E Pimenta et al than patients with essential hypertension and similar BP. After a mean 6.4 years of follow-up, reductions in both albuminuria and creatinine clearance were significantly greater in patients with PA treated with spironolactone or adrenalectomy than in patients with essential hypertension treated with other antihypertensive medications. BP reduction was comparable between the groups. Although the reduction in creatinine clearance in this study did not reach statistical significance, the significant and concomitant reduction in proteinuria and urinary volume after adrenalectomy supports the concept that filtration rate is an important mechanism in determining increased protein excretion in patients with aldosterone excess. The significant decrease in UNa excretion observed in our subjects following surgery raises the possibility that salt might be an important contributor to renal damage in patients with PA. Studies in humans and animals have demonstrated that salt intake is independently associated with increased proteinuria and vascular damage. [39] [40] [41] [42] [43] Our findings are in keeping with those of experimental studies, 16, 44 which have drawn attention to the importance of salt in the development of aldosteroneinduced renal (and other target-organ) damage. The significant decrease in UNa excretion after adrenalectomy may be caused by reduction in sodium appetite because of lowered aldosterone levels and, consequently, less activation of mineralocorticoid receptors in the brain. 45 In this study, there was a positive and significant correlation between proteinuria and salt before Urinary sodium (mEq/day) Urinary protein (mg/day) Figure 2 Linear regression correlations between 24-h urinary protein and 24-h urinary sodium excretion in patients with aldosterone-producing adenoma before (a) and after (b) adrenalectomy. adrenalectomy. Results from the current study, from our previously published human study 28 and from experiments in animals are all consistent with aldosterone excess and high dietary salt combining to increase Uprot excretion. In our previous study, 28 a positive correlation between Uprot and UNa was observed in subjects with resistant hypertension and high Ualdo, but not in subjects with similar BP and normal aldosterone levels.
Aldosterone may act through BP-independent pathological processes that lead to increased protein excretion in the urine. 46 In animal studies, aldosterone induces vasoconstriction of the efferent renal arteriole, thereby promoting protein excretion. 47, 48 Aldosterone directly promotes inflammation and fibrosis in renal tissue. 17 Salt decreases renal plasma flow, increases renal vascular resistance 49 and promotes renal fibrosis through increasing glomerular and tubular interstitial collagen volume fraction. 50 In this study, reduction in UNa was an independent predictor of Uprot reduction after adrenalectomy, suggesting that dietary salt, even after correction of aldosterone excess and BP reduction, remains an important determinant of kidney injury.
To our knowledge, our study is the first to examine the effects of unilateral adrenalectomy on the relationship between Uprot and sodium excretion in patients with unilateral PA. Perhaps surprisingly, adrenalectomy did not appear to correct the 'salt sensitivity', as demonstrated by a continuing positive correlation between Uprot and sodium after surgery. It is probable that longer-term renal effects of hyperaldosteronism and hypertension would have led to some irreversible glomerular damage and an ongoing tendency to salt-sensitive protein excretion. In this study, patients had an average 8-year history of hypertension and, probably, an even longer exposure to increased aldosterone levels. The slope of the regression remained similar before and after adrenalectomy, supporting the permanent damage hypothesis.
In a large cross-sectional investigation of 2700 participants from Framingham, subjects in the highest quintile of UNa had twofold higher albuminuria than those in the lowest quintile. 39 Similarly, albuminuria was 21% higher in subjects within the highest quintile of aldosterone compared with those in the lowest quintile. However, these investigators did not find that high-plasma aldosterone levels and high UNa excretion were additive in their effects on worsening albuminuria. The fact that most of the participants were normotensive (mean BP 128/76 mm Hg) and spot (rather than 24 h) urine collections were used for measuring UNa and albumin, may help to explain the disparity between their results and ours.
Salt and aldosterone have been recognized as independent predictors of CV morbidity and mortality. In a cross-sectional study, 124 patients with PA were compared with 465 control patients matched for severity and duration of hypertension. 51 Patients with PA were more than four times as likely to have had a stroke, 6.5 times as likely to have had a prior myocardial infarction, more than 12 times as likely to have developed atrial fibrillation and two to three times as likely to have left ventricular hypertrophy. 51 In a prospective study, 24 h UNa was correlated with CV morbidity and mortality in 2436 subjects aged 25-64 years. 52 A 100 mmol increase in 24 h UNa was associated with a 51% increase in incidence of coronary heart disease, 45% increase in CV disease and 26% increase in all-cause mortality. Our results suggest that high aldosterone levels combined with high dietary salt intake could be additive in contributing to increased CV risk.
Recent studies have linked aldosterone with the metabolic syndrome in general and with separate components of the syndrome. 53, 54 Correction of metabolic syndrome after adrenalectomy could contribute to reduce proteinuria or modify the relation between salt and protein excretion. However, the association between aldosterone and metabolic syndrome is not clear. 55, 56 Although we did not analyse specific components of the metabolic syndrome, body mass index did not change after adrenalectomy.
Mineralocorticoid receptor blockers have been successfully used in patients with hyperaldosteronism. Prospective studies have demonstrated that spironolactone significantly reduces proteinuria and CV morbidity and mortality in patients with PA. 27, 37, 57, 58 In our Hypertension Unit, all patients undergo FST after adrenalectomy to confirm biochemical resolution of autonomous, excessive aldosterone production. Patients who remain hypertensive after APA removal and show evidence of residual aldosterone autonomous production by post-operative FST are frequently treated with spironolactone (for example, 12.5 mg per day) or amiloride (for example, 2.5-7.5 mg per day) with careful monitoring of plasma potassium, renin and creatinine. Whether this treatment strategy provides additional target-organ protection in such patients has not been studied.
The current study is strengthened by its comprehensive diagnostic workup of PA and timed measurement of protein and sodium excretion in 24 h urine collections. Diagnosis of APA and its differentiation from bilateral adrenal hyperplasia was based on positive preoperative FST, lateralization by adrenal venous sampling using strict criteria 30, 59, 60 and resolution of PA (confirmed by negative postoperative FST) following unilateral adrenalectomy. Study limitations include its retrospective design and small number of patients. We did not need essential hypertensives as a control group, because previously published data from our group and others has already demonstrated a lack of correlation between Uprot and sodium excretion in patients without aldosterone excess. 28 , 61 We could not use PA patients before and after treatment with spironolactone as a control group, because spironolactone's action in the kidney would alter UNa excretion and confound interpretation. Furthermore, the lack of a control group was offset by obtaining observations before and after adrenalectomy, in which the subjects acted as their own controls. Our primary aim was to examine the effects of reversing aldosterone excess in patients with PA, and this was achieved.
In conclusion, correction of aldosterone excess by unilateral adrenalectomy in patients with APA significantly reduces Uprot excretion. A positive relationship between Uprot and sodium excretion exists not only before adrenalectomy, but also after. Experimental studies have demonstrated that aldosterone-induced pathological changes are dependent on concomitant high-salt diet, suggesting that the deleterious effect of aldosterone might be minimized or even prevented by reducing salt intake. Our study suggests that treatment strategies based on reduction of aldosterone effects, by adrenalectomy or mineralocorticoid receptor blockade, in conjunction with low-salt diet would provide additional target-organ protection in patients with PA.
